BAC2539
Various Cancers
Pre-clinicalActive
Key Facts
About Black Arrow Biotech
Black Arrow Biotech is a private, preclinical-stage company founded in 2020 that combines artificial intelligence with peptide therapeutics. Its proprietary AI platform, JÜRI, is claimed to accelerate the discovery and optimization of therapeutic peptides by over 45x compared to conventional methods. The company has an internal lead program, BAC2539, an RNA-based therapy for cancer, and also offers AI-powered screening and peptide library services to external researchers. While demonstrating promising early validation through academic collaboration, the company is pre-revenue and faces the typical risks of an early-stage AI-biotech hybrid.
View full company profileTherapeutic Areas
Other Various Cancers Drugs
| Drug | Company | Phase |
|---|---|---|
| Oncology/Immuno-oncology Portfolio | MSD | Phase III/Commercial |
| Bevacizumab Biosimilar | Dr. Reddy's Laboratories | Approved |
| LADR Platform | LadRx | Preclinical |
| NK Cell Stimulation (via JadiCell) | Therapeutic Solutions International | Preclinical |
| Zip-Code Library for Oncology | Kodikaz Therapeutic Solutions | Pre-clinical |
| Proprietary RLT Pipeline | Affibody | Not Specified (Preclinical-Phase 2) |
| Preclinical ASO Portfolio | Isarna Therapeutics | Preclinical |
| SPACE-GM Microenvironment Analysis | Enable Medicine | Research |
| Oncology Program(s) | CIS Pharma | Pre-clinical |
| Max Access Solutions (with The Max Foundation) | Tanner Pharma Group | N/A (Donation/Distribution Program) |
| CPA Platform in Oncology | InnoSIGN | Development |
| Oncology Services | Transcure Bioservices | Preclinical |